
Please try another search
(Updated - November 20, 2023 12:29 PM EST)
Investing.com -- U.S. stocks got off to a strong start, with all three major averages moving higher on Monday. The holiday-shortened week includes the keenly-awaited release of the minutes from the most recent Federal Reserve meeting.
Here are some of the biggest U.S. stock movers today:
Microsoft (NASDAQ:MSFT) stock rose 1.9% with the tech giant set to hire Sam Altman to lead a new advanced artificial intelligence research team, just days after the prominent AI-industry figure was ousted as CEO of OpenAI.
Nvidia (NASDAQ:NVDA) stock rose 1% ahead of Tuesday’s quarterly results, amid sky-high confidence the tech giant can outperform given the market’s enthusiasm for all things AI.
Uber (NYSE:UBER) stock gained 1% after the ride-hailing company announced plans to issue $1.2 billion of five-year convertible notes, subject to market conditions.
General Motors (NYSE:GM) stock rose 2.3% after Kyle Vogt, the CEO of the auto giant’s robot-taxi unit Cruise, resigned from the company as the company undergoes a safety review of its U.S. fleet.
Airbnb (ABNB) stock rose 2.2% after the short-term accommodation rental company appointed Ron Klain, a former top advisor to U.S. President Joe Biden, as its chief legal officer.
Boeing (NYSE:BA) stock rose 4.7% after Deutsche Bank upgraded its investment stance on the aircraft manufacturer to ‘buy’ from ‘hold’, citing increasing commercial jet deliveries.
Nikola (NASDAQ:NKLA) stock fell 4% after the electric-truck maker said Chief Financial Officer Anastasiya Pasterick would resign to "pursue other opportunities" less than a year after taking up the role.
KB Home (NYSE:KBH) declined 1.5% after analysts at Wedbush downgraded shares to Neutral from Outperform, citing competition and lack of catalysts.
Buenos Aires based energy company YPF S.A. (YPF) climbed 38% after Javier Milei won Argentina's presidential election.
Shares of Chegg (NYSE:CHGG) declined 6.4% following a downgrade by Morgan Stanley analysts to Underweight from Equal Weight. Analysts cited weaker trends observed in October and anticipated increased competition from generative artificial intelligence in the long term.
Shares of Bristol-Myers Squibb (NYSE:BMY) declined 2.6% after Bayer’s asundexian showed a lack of efficacy versus Eliquis in atrial fibrillation. The results were concerning for the Factor XIa class, including Bristol-Myers’s Milvexian.
Additional reporting by Louis Juricic
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.